Xencor Inc Cash Flow Conversion Efficiency
Xencor Inc cash flow conversion efficiency. Based on the latest financial reports, Xencor Inc (XNCR) has a cash flow conversion efficiency ratio of -0.049x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.82 Million) by net assets ($625.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Xencor Inc (2011–2024)
Cash flow conversion efficiency of Xencor Inc from 2011 to 2024. This chart illustrates how Xencor Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Xencor Inc share price for real-time trading data and today's change.
Xencor Inc Cash Flow Conversion Ratio Explained
Xencor Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Xencor Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xencor Inc ranked by their cash flow conversion efficiency. Also see Xencor Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Brainbees Solutions Limited
NSE:FIRSTCRY
|
-0.009x |
|
Tyntek Corp
TW:2426
|
0.005x |
|
Besalco Sa
SN:BESALCO
|
0.062x |
|
Xiamen International Airport Co Ltd
SHG:600897
|
0.041x |
|
Beijing CTJ Information Technology Co. Ltd.
SHE:301153
|
N/A |
|
Gallant Micro Machining Co Ltd
TWO:6640
|
0.040x |
|
Guangzhou Risong Intelligent Technology Holding Co Ltd
SHG:688090
|
0.048x |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
0.012x |
Annual Cash Flow Conversion Efficiency for Xencor Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Xencor Inc from 2011 to 2024. Review Xencor Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $674.03 Million | $-202.19 Million | -0.300x | -335.83% |
| 2023-12-31 | $669.13 Million | $85.11 Million | 0.127x | +277.92% |
| 2022-12-31 | $727.50 Million | $24.48 Million | 0.034x | +246.49% |
| 2021-12-31 | $733.50 Million | $-16.85 Million | -0.023x | -162.84% |
| 2020-12-31 | $572.44 Million | $-5.00 Million | -0.009x | -108.06% |
| 2019-12-31 | $593.20 Million | $64.37 Million | 0.109x | +170.98% |
| 2018-12-31 | $521.68 Million | $-79.76 Million | -0.153x | -28.02% |
| 2017-12-31 | $282.05 Million | $-33.68 Million | -0.119x | -139.63% |
| 2016-12-31 | $313.95 Million | $94.62 Million | 0.301x | +83.58% |
| 2015-12-31 | $162.43 Million | $26.67 Million | 0.164x | +145.59% |
| 2014-12-31 | $59.29 Million | $-21.35 Million | -0.360x | -385.61% |
| 2013-12-31 | $73.53 Million | $-5.45 Million | -0.074x | -113.09% |
| 2012-12-31 | $-19.50 Million | $-11.05 Million | 0.567x | +471.26% |
| 2011-12-31 | $-10.94 Million | $-1.08 Million | 0.099x | -- |
About Xencor Inc
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for t… Read more